Joseph Schwartz
Stock Analyst at Leerink Partners
(4.07)
# 533
Out of 5,090 analysts
157
Total ratings
33.09%
Success rate
20.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLT Applied Therapeutics | Downgrades: Market Perform | $2 → $1 | $0.22 | +361.68% | 3 | Dec 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $79.99 | +100.03% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $9.77 | +43.30% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.06 | +88.68% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $53.40 | +12.36% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.62 | +2.43% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $21.33 | +181.29% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $80.38 | +43.07% | 1 | Nov 10, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $71.63 | +0.52% | 4 | Oct 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $46.67 | +88.56% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $22.26 | -32.61% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $16.43 | +21.73% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $204.00 | -43.63% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $8.90 | +34.83% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $41.71 | -32.87% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $35.00 | +14.29% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.10 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.77 | +107.97% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.06 | +288.35% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.03 | -2.91% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $77.26 | -37.87% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $26.42 | -31.87% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $81.68 | -58.37% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $205.44 | -20.66% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.33 | +200.30% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.44 | +506.62% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $36.38 | +196.87% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $23.59 | +27.17% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $89.65 | -66.54% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.90 | +41.41% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.09 | +474.16% | 2 | Sep 26, 2017 |
Applied Therapeutics
Dec 3, 2025
Downgrades: Market Perform
Price Target: $2 → $1
Current: $0.22
Upside: +361.68%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $79.99
Upside: +100.03%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $9.77
Upside: +43.30%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.06
Upside: +88.68%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $53.40
Upside: +12.36%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.62
Upside: +2.43%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $21.33
Upside: +181.29%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $80.38
Upside: +43.07%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $71.63
Upside: +0.52%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $46.67
Upside: +88.56%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $22.26
Upside: -32.61%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $16.43
Upside: +21.73%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $204.00
Upside: -43.63%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.90
Upside: +34.83%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $41.71
Upside: -32.87%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $35.00
Upside: +14.29%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.77
Upside: +107.97%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.06
Upside: +288.35%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.03
Upside: -2.91%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $77.26
Upside: -37.87%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $26.42
Upside: -31.87%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $81.68
Upside: -58.37%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $205.44
Upside: -20.66%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.33
Upside: +200.30%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.44
Upside: +506.62%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $36.38
Upside: +196.87%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $23.59
Upside: +27.17%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $89.65
Upside: -66.54%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.90
Upside: +41.41%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.09
Upside: +474.16%